XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash flow from operating activities:    
Net loss $ (5,832,264) $ (6,011,680)
Adjustments to reconcile net loss to net cash used in operations    
Stock based compensation 646,970 405,058
Issuance of shares for services 1,325,128 805,329
Issuance of warrants for services, at fair value 272,630 474,232
Accretion expense, including day one derivative loss 879,416 901,296
Change in fair value of derivative liabilities 20,588 714,454
Fair value of warrants issued
Changes in operating assets and liabilities:    
Harmonized sales tax recoverable (27,052) 18,358
Deposits and other receivables (14,977) 838,492
Accounts payable and accrued liabilities (507,365) 16,613
Net Cash used in operating activities (3,236,926) (1,837,848)
Cash flows from financing activities:    
Issuance of shares, net 4,860,970  
Proceeds from exercise of warrants 428,311 105,500
Issuance of convertible debentures, net   1,899,700
Proceeds from issuance of stock options
Due to shareholders   (50,724)
Net Cash provided by financing activities 5,289,281 1,954,476
Effect of foreign currency translation 5,039 (149,612)
Net increase (decrease) in cash during the period 2,052,355 116,628
Cash, beginning of period 424,868 53,643
Cash, end of period $ 2,482,262 $ 20,659